The reduction in price target by JMP Securities from $16 to $8, despite maintaining a Market Outperform rating, could lead to a negative short-term sentiment among investors. This significant cut in the price target might be interpreted as a lack of confidence in the company's near-term growth prospects, potentially causing a decrease in Rallybio's stock price.